TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Henry Schein ( (HSIC) ) has issued an announcement.
James Breslawski, who transitioned from President to Senior Advisor at Henry Schein, Inc. on April 1, 2025, has now left his advisory role as of September 5, 2025. Following his departure, he will receive payments and benefits as per the company’s Executive Severance Plan.
The most recent analyst rating on (HSIC) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Henry Schein stock, see the HSIC Stock Forecast page.
Spark’s Take on HSIC Stock
According to Spark, TipRanks’ AI Analyst, HSIC is a Outperform.
Henry Schein’s overall stock score reflects stable financial performance and positive future growth prospects from strategic initiatives. However, technical indicators suggest a bearish trend, and valuation is moderate. The earnings call provided a positive outlook, but challenges in the U.S. dental market and cash flow issues remain concerns.
To see Spark’s full report on HSIC stock, click here.
More about Henry Schein
Henry Schein, Inc. operates in the healthcare industry, providing products and services primarily to dental and medical practitioners. The company focuses on delivering healthcare solutions and supplies to improve operational efficiency and patient care.
Average Trading Volume: 1,778,597
Technical Sentiment Signal: Sell
Current Market Cap: $8.42B
See more insights into HSIC stock on TipRanks’ Stock Analysis page.